1-9 of 9
Sam Yuen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Sorafenib plus intensive chemotherapy in newly diagnosed FLT3 -ITD AML: a randomized, placebo-controlled study by the ALLG

Clinical Trials & Observations
Sun Loo, Andrew W. Roberts, Natasha S. Anstee, Glen A. Kennedy, Simon He, Anthony P. Schwarer, Anoop K. Enjeti, James D’Rozario, Paula Marlton, Ian A. Bilmon, John Taper, Gavin Cull, Campbell Tiley, Emma Verner, Uwe Hahn, Devendra K. Hiwase, Harry J. Iland, Nick Murphy, Sundra Ramanathan, John Reynolds, Doen Ming Ong, Ing Soo Tiong, Meaghan Wall, Michael Murray, Tristan Rawling, Joanna Leadbetter, Leesa Rowley, Maya Latimer, Sam Yuen, Stephen B. Ting, Chun Yew Fong, Kirk Morris, Ashish Bajel, John F. Seymour, Mark J. Levis, Andrew H. Wei
Journal: Blood
Blood (2023) 142 (23): 1960–1971.
https://doi.org/10.1182/blood.2023020301
Published: 2023
Includes: Supplemental data
Journal Articles

The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma

Steven M. Horwitz, MD, Owen A. O'Connor, MD, Barbara Pro, MD, Tim Illidge, MD PhD, Swami P. Iyer, MD, Ranjana Advani, MD, Nancy L. Bartlett, MD, Jacob Haaber Christensen, Franck Morschhauser, MD, Eva Domingo-Domenech, MD, Giuseppe Rossi, MD, Won Seog Kim, PhD, Tatyana A. Feldman, MD, Tobias Menne, MD PhD, David Belada, MD PhD, Árpád Illés, MD PhD, Kensei Tobinai, MD, Kunihiro Tsukasaki, MD PhD, Su-Peng Yeh, MD, Andrei R Shustov, MD, Andreas Hüttmann, MD, Kerry J. Savage, BSc, MD MSc, Sam Yuen, MBBS, FRACP, FRCPA, Pier Luigi Zinzani, MD, Harry Miao, MD, Veronica Bunn, PhD, Keenan Fenton, MA, Michelle A. Fanale, MD, Markus Puhlmann, MD, Lorenz Truemper, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 3–5.
https://doi.org/10.1182/blood-2020-134398
Published: 2020
Journal Articles

Results of a Phase 2, Randomized, Double-Blind Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16)

Andrew H Wei, MBBS, PhD, Glen A Kennedy, MBBS FRACP FRCPA, Kirk L Morris, MBBA, FRACP, FRCPA, Andrew Grigg, MBBS, MD FRACP, FRCPA, Simon He, MBBS, FRACP, FRCPA, Anthony Schwarer, MBBS, MD FRACP, FRCPA, Stephen B Ting, MBBS, FRACP, FRCPA, PhD, Anoop Kumar Enjeti, MBBS,FRCPA, FRACP, PhD MD MRCP, Sam Yuen, MBBS, FRACP, FRCPA, James D'Rozario, MBBS, FRACP, FRCPA, Maya Latimer, MBBS, FRACP, FRCPA, Paula Marlton, MBBS FRACP FRCPA, Ian Bilmon, BMBS, FRACP, FRCPA, John Taper, MBBS, FRACP, FRCPA, B Pharm, Gavin Cull, MBBS, MD FRACP, FRCPA, Campbell Tiley, MBBS, FRACP, FRCPA, Emma Verner, MBBS, FRACP, FRCPA, Uwe H Hahn, MBBS, MD FRCPA, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, Harry Iland, MBBS, FRACP, FRCPA, MHGSA, Nichloas Murphy, MBBS, FRACP, FRCPA, Sundra Ravanathan, MBBS, FRACP, FRCPA, RCPA, Uyen Nguyen, Doen Ming Ong, MBBS, FRACP, FRCPA, RCPA, Sun Loo, MBBS, FRACP, FRCPA, RCPA, Ing-Soo Tiong, MBBS, FRACP, FRCPA, RCPA, Meaghan Wall, MBBS, FRACP, FRCPA, RCPA, PhD, Natasha S Anstee, PhD, Mark Levis, MD PhD, Michael Murray, PhD DSc, Tristan Rawling, PhD, Joanna Leadbetter, PhD, Ashish Bajel, FRACP, Andrew W Roberts, MBBS
Journal: Blood
Blood (2020) 136 (Supplement 1): 36–38.
https://doi.org/10.1182/blood-2020-137334
Published: 2020
Journal Articles

Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study

Giuseppe Gritti, MD PhD, Paula Marlton, MBBS FRACP FRCPA, Tycel J. Phillips, MD, Christopher Arthur, Rajat Bannerji, MDPhD, Paolo Corradini, Anna Johnston, John F. Seymour, Sam Yuen, MBBS, FRACP, FRCPA, Jamie Hirata, Lisa Musick, Sourish Saha, Brandon Croft, Christopher Flowers, MDMS
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–47.
https://doi.org/10.1182/blood-2020-136361
Published: 2020
Journal Articles

An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Consolidative Stem Cell Transplant

Kerry J Savage, BSc, MD MSc, Steven M. Horwitz, MD, Ranjana H Advani, MD, Jacob H. Christensen, MD, Eva Domingo-Domenech, MD, Giuseppe Rossi, Franck Morschhauser, MD, Onder Alpdogan, MD, Cheolwon Suh, Kensei Tobinai, MD PhD, Andrei R Shustov, MD, Marek Trneny, MD prof, Sam Yuen, MBBS,FRCPA,FRACP, Pier Luigi Zinzani, MD PhD, Lorenz Truemper, MD, Timothy Illidge, MD PhD, Owen O'Connor, MD PhD, Barbara Pro, MD, Meredith Little, MPH, Veronica Bunn, Keenan Fenton, Thomas Manley, MD, Swaminathan P. Iyer, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 464.
https://doi.org/10.1182/blood-2019-122781
Published: 2019
Journal Articles

The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas

Steven M. Horwitz, MD, Owen A. O'Connor, MD, PhD, Barbara Pro, MD, Tim M. Illidge, MDPhD, Michelle A. Fanale, MD, Ranjana H Advani, MD, Nancy L. Bartlett, MD, Jacob Haaber Christensen, Franck Morschhauser, MD, Eva Domingo-Domenech, MD, Giuseppe Rossi, MD, Won Seog Kim, MD PhD, Tatyana A. Feldman, MD, Anne Lennard, MBBS,FRCP, FRCPath, David Belada, MD PhD, Árpád Illés, Kensei Tobinai, MD PhD, Kunihiro Tsukasaki, MD PhD, Su-Peng Yeh, MD, Andrei R. Shustov, MD, Andreas Hüttmann, MD, Kerry J Savage, BSc, MD MSc, Sam Yuen, Pier Luigi Zinzani, MD, Zhaowei Hua, Meredith Little, MPH, Shangbang Rao, PhD, Joseph Woolery, PharmD, Thomas Manley, MD, Lorenz Trümper, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 997.
https://doi.org/10.1182/blood-2018-99-110563
Published: 2018
Journal Articles

Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Primary Analysis of a Phase I/II Study

Anas Younes, MD, John M Burke, Bruce Cheson, MD, Catherine Diefenbach, MD, Silvia Ferrari, Uwe Hahn, Eliza Hawkes, Cyrus Khan, Izidore S. Lossos, MD, Gerardo Musuraka, Monica Tani, Umberto Vitolo, Sam Yuen, Mikkel Z Oestergaard, Surya Chitra, Michael Wenger, Tina Nielsen, Gila Sellam, Jeff Sharman, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2969.
https://doi.org/10.1182/blood-2018-99-116678
Published: 2018
Journal Articles

Efficacy and Safety of Venetoclax (Ven) + Rituximab (R) or Ven + Bendamustine (B) + R Randomized Versus B + R in Patients (pts) with Relapsed/Refractory (R/R) Follicular Lymphoma (FL): Final Analysis of Phase II CONTRALTO Study

Pier Luigi Zinzani, MD, Ian W. Flinn, MD PhD, Sam Yuen, Max S. Topp, Chiara Rusconi, Isabelle Fleury, Christopher K Arthur, Barbara Pro, MD, Giuseppe Gritti, MD PhD, Michael Crump, Katell Le Du, MD, Divya Samineni, Arijit Sinha, Elizabeth A Punnoose, Edith Szafer-Glusman, Nathalie Danesi, Adam Petrich, Martin Kornacker, Kathryn Humphrey, Mehrdad Mobasher, MD MPH, Wolfgang Hiddemann
Journal: Blood
Blood (2018) 132 (Supplement 1): 1614.
https://doi.org/10.1182/blood-2018-99-116806
Published: 2018
Journal Articles

Safety and Efficacy of Atezolizumab in Combination with Obinutuzumab and Bendamustine in Patients with Previously Untreated Follicular Lymphoma: An Interim Analysis

Anas Younes, MD, Burke M. John, Catherine S Diefenbach, Silvia Ferrari, Cyrus Kahn, Jeffrey P. Sharman, MD, Monica Tani, Chaitra S. Ujjani, MD, Umberto Vitolo, MD, Sam Yuen, Paul Woodard, Kirsten Mundt, Günter Fingerle-Rowson, Surya Chitra, Gila Sellam, Rodica Morariu-Zamfir, Michael Gilbertson
Journal: Blood
Blood (2017) 130 (Supplement 1): 481.
https://doi.org/10.1182/blood.V130.Suppl_1.481.481
Published: 2017